AtriCure (NASDAQ:ATRC – Get Free Report) had its price objective cut by analysts at Canaccord Genuity Group from $57.00 to $49.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group’s target price indicates a potential upside of 120.52% from […]